← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $610B	4,551	+352	+8%	$367B
2	2 AbbVie ABBV $501B	4,173	+254	+6%	$301B
3	3 Merck MRK $358B	3,673	+354	+11%	$206B
4	4 Amgen AMGN $235B	3,098	+271	+10%	$147B
5	5 Pfizer PFE $168B	2,923	+103	+4%	$92.9B
6	6 Bristol-Myers Squibb BMY $124B	2,463	+186	+8%	$88.5B
7	7 Gilead Sciences GILD $195B	2,227	+193	+9%	$137B
8	8 Novartis NVS $286B	1,515	+110	+8%	$18.4B
9	9 AstraZeneca AZN $259B	1,409	+119	+9%	$46.4B
10	10 Regeneron Pharmaceuticals REGN $82B	1,390	+144	+12%	$70.7B
11	11 GSK GSK $98.2B	998	+101	+11%	$19.5B
12	12 Incyte INCY $23B	823	+109	+15%	$19.9B
13	13 Natera NTRA $58.3B	786	+100	+15%	$30.3B
14	14 DELISTED Exact Sciences EXAS	710	+141	+25%	$17.9B
15	15 Exelixis EXEL $15.6B	685	+64	+10%	$11.4B
16	16 Halozyme HALO $13.8B	619	+16	+3%	$8.29B
17	17 Jazz Pharmaceuticals JAZZ $13.9B	576	+73	+15%	$10.5B
18	18 Guardant Health GH $22.3B	497	+102	+26%	$13.4B
19	19 Tempus AI TEM $12.9B	457	+17	+4%	$5.96B
20	20 Lantheus LNTH $6.53B	393	-26	-6%	$4.62B
21	21 Revolution Medicines RVMD $40.6B	386	+63	+20%	$15.9B
22	22 Takeda Pharmaceutical TAK $62.1B	350	+19	+6%	$1.31B
23	23 Recursion Pharmaceuticals RXRX $2.23B	334	+12	+4%	$1.33B
24	24 Veracyte VCYT $3.57B	329	+31	+10%	$3.65B
25	25 Qiagen QGEN $9.53B	322	-18	-5%	$6.76B